Host |
Mouse |
Klon |
ZM352 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Positivkontrolle |
Spleen, bone marrow |
Verdünnung |
1:100 - 1:200 |
Isotyp |
IgG2b/κ |
Verdünnung |
Recombinant fragment (around aa150-250) of human MPO protein |
Lokalisation |
Cytoplasm |
Myeloperoxidase
|
Zeta Corporation |
ZM352 |
1 ml |
Concentrate |
CE/IVD |
Z2680ML |
-
|
Host |
Mouse |
Klon |
ZM352 |
Format |
Ready-to-use |
Reaktivität |
- |
Methode |
P |
Positivkontrolle |
Spleen, bone marrow |
Verdünnung |
- |
Isotyp |
IgG2b/κ |
Verdünnung |
Recombinant fragment (around aa150-250) of human MPO protein |
Lokalisation |
Cytoplasm |
Myeloperoxidase
|
Zeta Corporation |
ZM352 |
7 ml |
Ready-to-use |
CE/IVD |
Z2680MP |
-
|
Host |
Mouse |
Klon |
ZM352 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Positivkontrolle |
Spleen, bone marrow |
Verdünnung |
1:100 - 1:200 |
Isotyp |
IgG2b/κ |
Verdünnung |
Recombinant fragment (around aa150-250) of human MPO protein |
Lokalisation |
Cytoplasm |
Myeloperoxidase
|
Zeta Corporation |
ZM352 |
0.5 ml |
Concentrate |
CE/IVD |
Z2680MS |
-
|
Host |
Mouse |
Klon |
ZM352 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Positivkontrolle |
Spleen, bone marrow |
Verdünnung |
1:100 - 1:200 |
Isotyp |
IgG2b/κ |
Verdünnung |
Recombinant fragment (around aa150-250) of human MPO protein |
Lokalisation |
Cytoplasm |
Myeloperoxidase
|
Zeta Corporation |
ZM352 |
0.1 ml |
Concentrate |
CE/IVD |
Z2680MT |
-
|
Host |
Mouse |
Klon |
2C7 |
Format |
Purified |
Methode |
F, P, EL, WB, FL |
Positivkontrolle |
Bone Marrow |
Verdünnung |
1:500 - 1:1000 (P) |
Isotyp |
Mouse IgG1 |
Verdünnung |
Human myeloperoxidase |
Myeloperoxidase (MPO, pANCA)
|
Zytomed Systems GmbH |
2C7 |
200 µg |
Purified |
RUO |
613-0318 |
-
|
Host |
Mouse |
Klon |
2C7 |
Format |
Purified |
Methode |
F, P, FL |
Positivkontrolle |
Bone Marrow |
Verdünnung |
1:500 - 1:1000 (P) |
Isotyp |
Mouse IgG1 |
Verdünnung |
Human myeloperoxidase |
Myeloperoxidase (MPO, pANCA)
|
Zytomed Systems GmbH |
2C7 |
20 µg |
Purified |
RUO |
613-0319 |
-
|
Host |
Rabbit |
Klon |
SP72 |
Format |
Concentrate |
Methode |
P |
Vorbehandlung |
Citrate |
Positivkontrolle |
Tonsil |
Verdünnung |
1:100 |
Isotyp |
Rabbit IgG |
Verdünnung |
A synthetic peptide corresponding to C-terminus of human myeloperoxidase protein |
Lokalisation |
Cytoplasm |
Myeloperoxidase (MPO)
|
Zytomed Systems GmbH |
SP72 |
0.1 ml |
Concentrate |
RUO |
513-3720 |
-
|
Host |
Mouse |
Klon |
59A5 |
Format |
Concentrate |
Methode |
F, P |
Vorbehandlung |
Citrate |
Positivkontrolle |
Tonsil |
Verdünnung |
1:25 - 1:50 |
Isotyp |
Mouse IgG2b kappa |
Verdünnung |
Recombinant protein corresponding to 101 amino acids from exon 7 of human myeloperoxidase |
Lokalisation |
Cytoplasm |
Myeloperoxidase (MPO)
|
Diagnostic Biosystems |
59A5 |
1 ml |
Concentrate |
CE/IVD |
MOB551 |
-
|
Host |
Mouse |
Klon |
59A5 |
Format |
Concentrate |
Methode |
F, P |
Vorbehandlung |
Citrate |
Positivkontrolle |
Tonsil |
Verdünnung |
1:25 - 1:50 |
Isotyp |
Mouse IgG2b kappa |
Verdünnung |
Recombinant protein corresponding to 101 amino acids from exon 7 of human myeloperoxidase |
Lokalisation |
Cytoplasm |
Myeloperoxidase (MPO)
|
Diagnostic Biosystems |
59A5 |
0.1 ml |
Concentrate |
CE/IVD |
MOB551-01 |
-
|
Host |
Mouse |
Klon |
59A5 |
Format |
Concentrate |
Methode |
F, P |
Vorbehandlung |
Citrate |
Positivkontrolle |
Tonsil |
Verdünnung |
1:25 - 1:50 |
Isotyp |
Mouse IgG2b kappa |
Verdünnung |
Recombinant protein corresponding to 101 amino acids from exon 7 of human myeloperoxidase |
Lokalisation |
Cytoplasm |
Myeloperoxidase (MPO)
|
Diagnostic Biosystems |
59A5 |
0.5 ml |
Concentrate |
CE/IVD |
MOB551-05 |
-
|
Host |
Mouse |
Klon |
59A5 |
Format |
Ready-to-use |
Methode |
F, P |
Vorbehandlung |
Citrate |
Positivkontrolle |
Tonsil |
Verdünnung |
- |
Isotyp |
Mouse IgG2b kappa |
Verdünnung |
Recombinant protein corresponding to 101 amino acids from exon 7 of human myeloperoxidase |
Lokalisation |
Cytoplasm |
Myeloperoxidase (MPO)
|
Diagnostic Biosystems |
59A5 |
6 ml |
Ready-to-use |
CE/IVD |
PDM551 |
-
|
Host |
Rabbit |
Klon |
polyclonal |
Format |
Ready-to-use |
Methode |
F, P |
Vorbehandlung |
Citrate |
Positivkontrolle |
Tonsil |
Verdünnung |
- |
Isotyp |
Rabbit IgG |
Lokalisation |
Cytoplasm |
Myeloperoxidase (MPO)
|
Diagnostic Biosystems |
polyclonal |
6 ml |
Ready-to-use |
CE/IVD |
PDR049 |
-
|
Host |
Rabbit |
Klon |
polyclonal |
Format |
Concentrate |
Methode |
F, P |
Vorbehandlung |
Citrate |
Positivkontrolle |
Tonsil |
Verdünnung |
1:25 - 1:100 |
Isotyp |
Rabbit IgG |
Lokalisation |
Cytoplasm |
Myeloperoxidase (MPO)
|
Diagnostic Biosystems |
polyclonal |
1 ml |
Concentrate |
CE/IVD |
RP053 |
-
|
Host |
Rabbit |
Klon |
polyclonal |
Format |
Concentrate |
Methode |
F, P |
Vorbehandlung |
Citrate |
Positivkontrolle |
Tonsil |
Verdünnung |
1:25 - 1:100 |
Isotyp |
Rabbit IgG |
Lokalisation |
Cytoplasm |
Myeloperoxidase (MPO)
|
Diagnostic Biosystems |
polyclonal |
0.1 ml |
Concentrate |
CE/IVD |
RP053-01 |
-
|
Host |
Rabbit |
Klon |
polyclonal |
Format |
Concentrate |
Methode |
F, P |
Vorbehandlung |
Citrate |
Positivkontrolle |
Tonsil |
Verdünnung |
1:25 - 1:100 |
Isotyp |
Rabbit IgG |
Lokalisation |
Cytoplasm |
Myeloperoxidase (MPO)
|
Diagnostic Biosystems |
polyclonal |
0.5 ml |
Concentrate |
CE/IVD |
RP053-05 |
-
|
Host |
Mouse |
Klon |
5.2F |
Format |
Concentrate |
Methode |
P |
Vorbehandlung |
Citrate |
Positivkontrolle |
Tonsil |
Verdünnung |
1:25 - 1:50 |
Isotyp |
Mouse IgG2a |
Lokalisation |
Nucleus |
MyoD1
|
Diagnostic Biosystems |
5.2F |
1 ml |
Concentrate |
CE/IVD |
MOB278 |
-
|
Host |
Mouse |
Klon |
5.2F |
Format |
Concentrate |
Methode |
P |
Vorbehandlung |
Citrate |
Positivkontrolle |
Tonsil |
Verdünnung |
1:25 - 1:50 |
Isotyp |
Mouse IgG2a |
Lokalisation |
Nucleus |
MyoD1
|
Diagnostic Biosystems |
5.2F |
0.1 ml |
Concentrate |
CE/IVD |
MOB278-01 |
-
|
Host |
Mouse |
Klon |
5.2F |
Format |
Concentrate |
Methode |
P |
Vorbehandlung |
Citrate |
Positivkontrolle |
Tonsil |
Verdünnung |
1:25 - 1:50 |
Isotyp |
Mouse IgG2a |
Lokalisation |
Nucleus |
MyoD1
|
Diagnostic Biosystems |
5.2F |
0.5 ml |
Concentrate |
CE/IVD |
MOB278-05 |
-
|
Host |
Mouse |
Klon |
5.2F |
Format |
Ready-to-use |
Methode |
P |
Vorbehandlung |
Citrate |
Positivkontrolle |
Tonsil |
Verdünnung |
- |
Isotyp |
Mouse IgG2a |
Lokalisation |
Nucleus |
MyoD1
|
Diagnostic Biosystems |
5.2F |
6 ml |
Ready-to-use |
CE/IVD |
PDM120 |
-
|
Host |
Rabbit |
Klon |
ZR262 |
Format |
Concentrate |
Methode |
P |
Positivkontrolle |
Rhabdomyosarcoma |
Verdünnung |
1:100 - 1:200 |
Isotyp |
IgG |
Lokalisation |
Nuclear and cytoplasmic |
MyoD1
|
Zeta Corporation |
ZR262 |
1 ml |
Concentrate |
CE/IVD |
Z2576RL |
-
|
Host |
Rabbit |
Klon |
ZR262 |
Format |
Ready-to-use |
Methode |
P |
Positivkontrolle |
Rhabdomyosarcoma |
Verdünnung |
RTU |
Isotyp |
IgG |
Lokalisation |
Nuclear and cytoplasmic |
MyoD1
|
Zeta Corporation |
ZR262 |
7.0 ml |
Ready-to-use |
CE/IVD |
Z2576RP |
-
|
Host |
Rabbit |
Klon |
ZR262 |
Format |
Concentrate |
Methode |
P |
Positivkontrolle |
Rhabdomyosarcoma |
Verdünnung |
1:100 - 1:200 |
Isotyp |
IgG |
Lokalisation |
Nuclear and cytoplasmic |
MyoD1
|
Zeta Corporation |
ZR262 |
0.5 ml |
Concentrate |
CE/IVD |
Z2576RS |
-
|
Host |
Rabbit |
Klon |
ZR262 |
Format |
Concentrate |
Methode |
P |
Positivkontrolle |
Rhabdomyosarcoma |
Verdünnung |
1:100 - 1:200 |
Isotyp |
IgG |
Lokalisation |
Nuclear and cytoplasmic |
MyoD1
|
Zeta Corporation |
ZR262 |
0.1 ml |
Concentrate |
CE/IVD |
Z2576RT |
-
|
Host |
Mouse |
Klon |
F5D |
Format |
Concentrate |
Methode |
F, P, WB, IP, IF |
Vorbehandlung |
Citrate |
Positivkontrolle |
Rhabdomyosarcoma |
Verdünnung |
1:50 - 1:100 |
Isotyp |
Mouse IgG1 |
Lokalisation |
Nucleus |
Myogenin
|
Diagnostic Biosystems |
F5D |
1 ml |
Concentrate |
CE/IVD |
MOB322 |
-
|
Host |
Mouse |
Klon |
F5D |
Format |
Concentrate |
Methode |
F, P, WB, IP, IF |
Vorbehandlung |
Citrate |
Positivkontrolle |
Rhabdomyosarcoma |
Verdünnung |
1:50 - 1:100 |
Isotyp |
Mouse IgG1 |
Lokalisation |
Nucleus |
Myogenin
|
Diagnostic Biosystems |
F5D |
0.1 ml |
Concentrate |
CE/IVD |
MOB322-01 |
-
|
Host |
Mouse |
Klon |
F5D |
Format |
Concentrate |
Methode |
F, P, WB, IP, IF |
Vorbehandlung |
Citrate |
Positivkontrolle |
Rhabdomyosarcoma |
Verdünnung |
1:50 - 1:100 |
Isotyp |
Mouse IgG1 |
Lokalisation |
Nucleus |
Myogenin
|
Diagnostic Biosystems |
F5D |
0.5 ml |
Concentrate |
CE/IVD |
MOB322-05 |
-
|
Host |
Mouse |
Klon |
F5D |
Format |
Ready-to-use |
Methode |
F, P |
Vorbehandlung |
Citrate |
Positivkontrolle |
Rhabdomyosarcoma |
Verdünnung |
- |
Isotyp |
Mouse IgG1 |
Lokalisation |
Nucleus |
Myogenin
|
Diagnostic Biosystems |
F5D |
6 ml |
Ready-to-use |
CE/IVD |
PDM158 |
-
|
Host |
Mouse |
Klon |
F5D |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Positivkontrolle |
Rhabdomyosarcoma. |
Verdünnung |
1:100 - 1:200 |
Isotyp |
IgG1 /κ |
Verdünnung |
Recombinant protein containing rat myogenin aa 30-224 |
Lokalisation |
Nucleus |
Myogenin
|
Zeta Corporation |
F5D |
1ml |
Concentrate |
CE/IVD |
Z2054ML |
-
|
Host |
Mouse |
Klon |
F5D |
Format |
Ready-to-use |
Reaktivität |
- |
Methode |
P |
Positivkontrolle |
Rhabdomyosarcoma. |
Verdünnung |
- |
Isotyp |
IgG1 /κ |
Verdünnung |
Recombinant protein containing rat myogenin aa 30-224 |
Lokalisation |
Nucleus |
Myogenin
|
Zeta Corporation |
F5D |
7 ml |
Ready-to-use |
CE/IVD |
Z2054MP |
-
|
Host |
Mouse |
Klon |
F5D |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Positivkontrolle |
Rhabdomyosarcoma. |
Verdünnung |
1:100 - 1:200 |
Isotyp |
IgG1 /κ |
Verdünnung |
Recombinant protein containing rat myogenin aa 30-224 |
Lokalisation |
Nucleus |
Myogenin
|
Zeta Corporation |
F5D |
0.5 ml |
Concentrate |
CE/IVD |
Z2054MS |
-
|
Host |
Mouse |
Klon |
F5D |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Positivkontrolle |
Rhabdomyosarcoma. |
Verdünnung |
1:100 - 1:200 |
Isotyp |
IgG1 /κ |
Verdünnung |
Recombinant protein containing rat myogenin aa 30-224 |
Lokalisation |
Nucleus |
Myogenin
|
Zeta Corporation |
F5D |
0.1 ml |
Concentrate |
CE/IVD |
Z2054MT |
-
|
Host |
Mouse |
Klon |
ZM149 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Positivkontrolle |
Rhabdomyosarcoma or Wilm's tumor. |
Verdünnung |
1:100 - 1:200 |
Isotyp |
IgG1 /κ |
Verdünnung |
Human myogenin recombinant protein |
Lokalisation |
Nucleus |
Myogenin
|
Zeta Corporation |
ZM149 |
1.0 ml |
Concentrate |
CE/IVD |
Z2462ML |
-
|
Host |
Mouse |
Klon |
ZM149 |
Format |
Ready-to-use |
Reaktivität |
- |
Methode |
P |
Positivkontrolle |
Rhabdomyosarcoma or Wilm's tumor. |
Verdünnung |
- |
Isotyp |
IgG1 /κ |
Verdünnung |
Human myogenin recombinant protein |
Lokalisation |
Nucleus |
Myogenin
|
Zeta Corporation |
ZM149 |
7 ml |
Ready-to-use |
CE/IVD |
Z2462MP |
-
|
Host |
Mouse |
Klon |
ZM149 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Positivkontrolle |
Rhabdomyosarcoma or Wilm's tumor. |
Verdünnung |
1:100 - 1:200 |
Isotyp |
IgG1 /κ |
Verdünnung |
Human myogenin recombinant protein |
Lokalisation |
Nucleus |
Myogenin
|
Zeta Corporation |
ZM149 |
0.5 ml |
Concentrate |
CE/IVD |
Z2462MS |
-
|
Host |
Mouse |
Klon |
ZM149 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Positivkontrolle |
Rhabdomyosarcoma or Wilm's tumor. |
Verdünnung |
1:100 - 1:200 |
Isotyp |
IgG1 /κ |
Verdünnung |
Human myogenin recombinant protein |
Lokalisation |
Nucleus |
Myogenin
|
Zeta Corporation |
ZM149 |
0.1 ml |
Concentrate |
CE/IVD |
Z2462MT |
-
|
Host |
Mouse |
Klon |
MY32 |
Format |
Concentrate |
Methode |
F, P |
Positivkontrolle |
Skeletal Muscle |
Verdünnung |
1:25 - 1:50 |
Isotyp |
Mouse IgG1 |
Lokalisation |
Cytoplasm |
Myosin (Skeletal Muscle)
|
Diagnostic Biosystems |
MY32 |
1 ml |
Concentrate |
CE/IVD |
MOB207 |
-
|
Host |
Mouse |
Klon |
MY32 |
Format |
Concentrate |
Methode |
F, P |
Positivkontrolle |
Skeletal Muscle |
Verdünnung |
1:25 - 1:50 |
Isotyp |
Mouse IgG1 |
Lokalisation |
Cytoplasm |
Myosin (Skeletal Muscle)
|
Diagnostic Biosystems |
MY32 |
0.1 ml |
Concentrate |
CE/IVD |
MOB207-01 |
-
|
Host |
Mouse |
Klon |
MY32 |
Format |
Concentrate |
Methode |
F, P |
Positivkontrolle |
Skeletal Muscle |
Verdünnung |
1:25 - 1:50 |
Isotyp |
Mouse IgG1 |
Lokalisation |
Cytoplasm |
Myosin (Skeletal Muscle)
|
Diagnostic Biosystems |
MY32 |
0.5 ml |
Concentrate |
CE/IVD |
MOB207-05 |
-
|
Host |
Mouse |
Klon |
MY32 |
Format |
Ready-to-use |
Methode |
F, P |
Positivkontrolle |
Skeletal Muscle |
Verdünnung |
- |
Isotyp |
Mouse IgG1 |
Lokalisation |
Cytoplasm |
Myosin (Skeletal Muscle)
|
Diagnostic Biosystems |
MY32 |
6 ml |
Ready-to-use |
CE/IVD |
PDM085 |
-
|
Host |
Mouse |
Klon |
SMMS-1 |
Format |
Concentrate |
Methode |
F, P |
Vorbehandlung |
Citrate |
Positivkontrolle |
Colon, appendix |
Verdünnung |
1:100 - 1:500 |
Isotyp |
Mouse IgG1 |
Verdünnung |
Human uterus smooth muscle extract |
Lokalisation |
Cytoplasm |
Myosin SM
|
Diagnostic Biosystems |
SMMS-1 |
1 ml |
Concentrate |
CE/IVD |
MOB467 |
-
|
Host |
Mouse |
Klon |
SMMS-1 |
Format |
Concentrate |
Methode |
F, P |
Vorbehandlung |
Citrate |
Positivkontrolle |
Colon, appendix |
Verdünnung |
1:100 - 1:500 |
Isotyp |
Mouse IgG1 |
Verdünnung |
Human uterus smooth muscle extract |
Lokalisation |
Cytoplasm |
Myosin SM
|
Diagnostic Biosystems |
SMMS-1 |
0.1 ml |
Concentrate |
CE/IVD |
MOB467-01 |
-
|
Host |
Mouse |
Klon |
SMMS-1 |
Format |
Concentrate |
Methode |
F, P |
Vorbehandlung |
Citrate |
Positivkontrolle |
Colon, appendix |
Verdünnung |
1:100 - 1:500 |
Isotyp |
Mouse IgG1 |
Verdünnung |
Human uterus smooth muscle extract |
Lokalisation |
Cytoplasm |
Myosin SM
|
Diagnostic Biosystems |
SMMS-1 |
0.5 ml |
Concentrate |
CE/IVD |
MOB467-05 |
-
|
Host |
Mouse |
Klon |
SMMS-1 |
Format |
Ready-to-use |
Methode |
F, P |
Vorbehandlung |
Citrate |
Positivkontrolle |
Colon, appendix |
Verdünnung |
- |
Isotyp |
Mouse IgG1 |
Verdünnung |
Human uterus smooth muscle extract |
Lokalisation |
Cytoplasm |
Myosin SM
|
Diagnostic Biosystems |
SMMS-1 |
6 ml |
Ready-to-use |
CE/IVD |
PDM175 |
-
|
Host |
Mouse |
Klon |
SMMS-1 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Positivkontrolle |
Transitional cell carcinoma. |
Verdünnung |
1:100 - 1:200 |
Isotyp |
IgG1 /κ |
Verdünnung |
Crude human uterus extract |
Lokalisation |
Nucleus |
Myosin, SMHC
|
Zeta Corporation |
SMMS-1 |
1ml |
Concentrate |
CE/IVD |
Z2229ML |
-
|
Host |
Mouse |
Klon |
SMMS-1 |
Format |
Ready-to-use |
Reaktivität |
- |
Methode |
P |
Positivkontrolle |
Transitional cell carcinoma. |
Verdünnung |
- |
Isotyp |
IgG1 /κ |
Verdünnung |
Crude human uterus extract |
Lokalisation |
Nucleus |
Myosin, SMHC
|
Zeta Corporation |
SMMS-1 |
7 ml |
Ready-to-use |
CE/IVD |
Z2229MP |
-
|
Host |
Mouse |
Klon |
SMMS-1 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Positivkontrolle |
Transitional cell carcinoma. |
Verdünnung |
1:100 - 1:200 |
Isotyp |
IgG1 /κ |
Verdünnung |
Crude human uterus extract |
Lokalisation |
Nucleus |
Myosin, SMHC
|
Zeta Corporation |
SMMS-1 |
0.5 ml |
Concentrate |
CE/IVD |
Z2229MS |
-
|
Host |
Mouse |
Klon |
SMMS-1 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Positivkontrolle |
Transitional cell carcinoma. |
Verdünnung |
1:100 - 1:200 |
Isotyp |
IgG1 /κ |
Verdünnung |
Crude human uterus extract |
Lokalisation |
Nucleus |
Myosin, SMHC
|
Zeta Corporation |
SMMS-1 |
0.1 ml |
Concentrate |
CE/IVD |
Z2229MT |
-
|
Host |
Rabbit |
Klon |
BC15 |
Format |
Concentrate |
Methode |
P |
Vorbehandlung |
Diva modified Citrate pH 6.2 |
Positivkontrolle |
Lung adenocarcinoma |
Verdünnung |
1:100 - 1:200 |
Isotyp |
Rabbit IgG |
Lokalisation |
Cytoplasmic (granular) |
Napsin A
|
Biocare Medical |
BC15 |
0.1 ml |
Concentrate |
CE/IVD |
ACI3043A |
-
|
Host |
Rabbit |
Klon |
BC15 |
Format |
Concentrate |
Methode |
P |
Vorbehandlung |
Diva modified Citrate pH 6.2 |
Positivkontrolle |
Lung adenocarcinoma |
Verdünnung |
1:100 - 1:200 |
Isotyp |
Rabbit IgG |
Lokalisation |
Cytoplasmic (granular) |
Napsin A
|
Biocare Medical |
BC15 |
1 ml |
Concentrate |
CE/IVD |
ACI3043C |
-
|
Host |
Rabbit |
Klon |
BC15 |
Format |
Ready-to-use |
Methode |
P |
Vorbehandlung |
Diva modified Citrate pH 6.2 |
Positivkontrolle |
Lung adenocarcinoma |
Verdünnung |
- |
Isotyp |
Rabbit IgG |
Lokalisation |
Cytoplasmic (granular) |
Napsin A
|
Biocare Medical |
BC15 |
6 ml |
Ready-to-use |
CE/IVD |
API3043AA |
-
|